James Hippel - Aug 6, 2021 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Signature
/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.
Stock symbol
TECH
Transactions as of
Aug 6, 2021
Transactions value $
-$4,525,322
Form type
4
Date filed
8/10/2021, 06:21 PM
Previous filing
Jul 14, 2021
Next filing
Sep 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $0 +3.38K +37.03% $0.00 12.5K Aug 8, 2021 Direct
transaction TECH Common Stock Tax liability -$802K -1.67K -13.3% $481.82* 10.9K Aug 8, 2021 Direct
transaction TECH Common Stock Options Exercise $1.07M +10K +92.12% $106.59 20.9K Aug 9, 2021 Direct
transaction TECH Common Stock Sale -$2.48M -5.2K -24.93% $477.69* 15.7K Aug 9, 2021 Direct F1
transaction TECH Common Stock Sale -$861K -1.8K -11.5% $478.58* 13.9K Aug 9, 2021 Direct F2
transaction TECH Common Stock Sale -$624K -1.3K -9.38% $479.96* 12.6K Aug 9, 2021 Direct F3
transaction TECH Common Stock Sale -$48.1K -100 -0.8% $480.70* 12.5K Aug 9, 2021 Direct F4
transaction TECH Common Stock Sale -$336K -700 -5.62% $480.66* 11.8K Aug 9, 2021 Direct F5
transaction TECH Common Stock Sale -$144K -300 -2.55% $481.61* 11.5K Aug 9, 2021 Direct F6
transaction TECH Common Stock Sale -$145K -300 -2.62% $483.62* 11.2K Aug 9, 2021 Direct F7
transaction TECH Common Stock Sale -$145K -300 -2.69% $484.98* 10.9K Aug 9, 2021 Direct F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -10K -50% $0.00 10K Aug 9, 2021 Common Stock 10K $106.59 Direct F10
transaction TECH Restricted Stock Units Options Exercise $0 -3.38K -100% $0.00* 0 Aug 8, 2021 Common Stock 3.38K Direct F9, F11
transaction TECH Restricted Stock Units Award $0 +1.95K $0.00 1.95K Aug 6, 2021 Common Stock 1.95K Direct F9, F19
transaction TECH Stock Options (Right to Buy) Award $0 +7.6K $0.00 7.6K Aug 6, 2021 Common Stock 7.6K $481.82 Direct F19
transaction TECH Stock Options (Right to Buy) Award $0 +10.1K $0.00 10.1K Aug 6, 2021 Common Stock 10.1K $481.82 Direct F20
holding TECH Stock Options (Right to Buy) 24.5K Aug 6, 2021 Common Stock 24.5K $125.05 Direct F10
holding TECH Stock Options (Right to Buy) 32.6K Aug 6, 2021 Common Stock 32.6K $125.05 Direct F10
holding TECH Stock Options (Right to Buy) 18.1K Aug 6, 2021 Common Stock 18.1K $177.32 Direct F11
holding TECH Stock Options (Right to Buy) 24.1K Aug 6, 2021 Common Stock 24.1K $177.32 Direct F12
holding TECH Restricted Stock Units 3.94K Aug 6, 2021 Common Stock 3.94K Direct F9, F11, F13
holding TECH Stock Options (Right to Buy) 19.9K Aug 6, 2021 Common Stock 19.9K $190.41 Direct F13
holding TECH Stock Options (Right to Buy) 26.6K Aug 6, 2021 Common Stock 26.6K $190.41 Direct F14
holding TECH Restricted Stock Units 3.22K Aug 6, 2021 Common Stock 3.22K Direct F9, F15
holding TECH Stock Options (Right to Buy) 14.4K Aug 6, 2021 Common Stock 14.4K $267.87 Direct F15
holding TECH Stock Options (Right to Buy) 19.1K Aug 6, 2021 Common Stock 19.1K $267.87 Direct F16
holding TECH Stock Options (Right to Buy) 8.33K Aug 6, 2021 Common Stock 8.33K $267.87 Direct F17
holding TECH Stock Options (Right to Buy) 8.33K Aug 6, 2021 Common Stock 8.33K $267.87 Direct F18
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $477.20 to $478.13, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $478.25 to $479.12, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.69 to $480.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.70 to $480.70, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.23 to $481.185, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.49 to $481.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.59 to $483.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.64 to $485.4475, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
F10 Fully exercisable.
F11 Vested in full on 8/8/2021 upon the certification of achievement of performance goals.
F12 Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.
F13 Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14 Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
F15 Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F16 Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.
F17 Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F18 Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F19 Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F20 Options to purchase 2,534 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vest on each of 8/6/2024 and 8/6/2025.